TTR and cancer: Since the approval of the first siRNA therapeutic, ONPATTROTM (Patisiran), for the treatment of transthyretin‐mediated amyloidosis,40 more and more siRNA therapeutics are under clinical trials for diverse diseases, especially cancers.41